Feb 26, 2020
iOnctura Announces First Patient Dosed in a Phase I Clinical Study of its Novel Highly Selective PI3Kd Inhibitor, IOA-244 for Solid Tumours
Jan 23, 2020
iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Development
Dec 10, 2019
Caris Life Sciences to Present Data Evaluating PI3K Pathway Alterations at the 2019 San Antonio Breast Cancer Symposium (SABCS)
Sep 23, 2019
MEI Pharma to Host Investor and Analyst Event on October 4, 2019
Jul 23, 2019
The PI3K inhibitors market is forescasted to grow at a CAGR of about 5% during the forecast period
Jul 12, 2019
Zydelig (idelalisib; Gilead) Drug Overview 2019: An Oral, Highly Selective Inhibitor of the Phosphoinositide 3-Kinase (PI3K) Isoform p110-delta
Jul 08, 2019
Copiktra (Duvelisib; Verastem/Yakult Honsha) Drug Overview & Product Profiles 2017-2026
Jul 01, 2019
Global Aliqopa (Copanlisib; Bayer) Drug Profile 2019: A Small Molecule Phosphoinositide 3-Kinase (PI3K) Inhibitor with High Selectivity for the p110-alpha/delta Catalytic Subunits
May 08, 2019
New positive data from phase IIa trial in brain cancer patients
Apr 02, 2019
Petra Pharma Strengthens Management Team With Recent Leadership Appointments
Feb 28, 2019
iOnctura Selected for an Oral Presentation at 2019 AACR Annual Meeting
Oct 29, 2018
Progress Update on GDC-0084 Program
Oct 16, 2018
Catalent and Verastem Oncology Partner on Newly Launched, FDA Approved COPIKTRA(TM) (duvelisib) Capsules
Apr 13, 2018
Menarini Ricerche to Present the Most Recent Pre-clinical Data About the PI3K Inhibitor MEN1611 at the AACR Annual Meeting 2018
Mar 28, 2018
Commencement Of Phase II Clinical Study Of GDC-0084
Dec 13, 2017
AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer
Aug 22, 2017
GDC-0084 Progress Update: On Track for Phase II Commencement in 2017
Jul 27, 2017
Infinity Amends PI3K-Delta,Gamma Agreement with Takeda Oncology
Jun 21, 2017
NovellusDx Announced Today the Completion of the First Phase of an In-vitro Study of BioMed Valley Discoveries' BVD523